By Victor Nwegede
From the protective barrier of condoms in the 1980s to daily antiretroviral tablets, injections administered every two months and the emergence of six-monthly lenacapavir, human immunodeficiency virus (HIV) prevention has undergone an extraordinary scientific transformation. But as Nigeria embraces a new generation of biomedical interventions, questions surrounding affordability, accessibility, public awareness, stigma and healthcare preparedness remain central to the country's ambition of ending acquired immunodeficiency syndrome (AIDS) as a public health threat.
According to available scientific and historical records and documentation from the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the National Agency for the Control of AIDS (NACA), among other institutions, the battle against HIV for more than four decades has been characterised by scientific breakthroughs, public health campaigns, social resistance, human rights advocacy and an unrelenting search for more effective ways of preventing transmission.
What began in the early 1980s as a frightening epidemic surrounded by uncertainty, misinformation, discrimination and widespread misconceptions has progressively evolved into a public health response offering several scientifically established prevention options.
At the centre of this transformation is an important development: HIV prevention is no longer dependent exclusively on abstinence, faithfulness, behavioural modification and condom use. Although these conventional interventions remain relevant, medical science has significantly expanded the prevention landscape through antiretroviral-based interventions, including oral pre-exposure prophylaxis (PrEP), long-acting injectable cabotegravir (CAB-LA) and, more recently, lenacapavir, a groundbreaking injectable administered twice yearly for HIV prevention.
This evolution represents more than a change in medication. It reflects a fundamental shift towards individual choice, differentiated healthcare delivery and preventive technologies that increasingly address some of the limitations associated with conventional approaches.
However, the emergence of these innovations also raises a critical question for Nigeria: can the country translate scientific advancement into affordable, accessible and sustainable protection for the millions of people who need HIV prevention services?
This question formed an important backdrop to a two-day national media training organised by NACA in collaboration with the Institute of Human Virology Nigeria (IHVN) in Lagos recently. The engagement brought together journalists and media professionals from different parts of the country to deepen their understanding of HIV prevention, particularly PrEP, and strengthen their capacity to communicate accurate, evidence-based information to the public. Beyond the technical presentations, the training provided an opportunity to examine the historical evolution of HIV prevention, the science underpinning emerging technologies and the responsibility of the media in ensuring that medical breakthroughs translate into informed public choices.
Historical accounts indicate that the early 1980s marked a defining period in modern public health history. Following the identification of AIDS cases in 1981 and the subsequent identification of HIV as the virus responsible for the condition, governments, researchers and international health organisations confronted an unprecedented challenge. There was no effective treatment, no approved preventive medication and no vaccine, resulting in widespread fear, uncertainty and confusion.
Consequently, public health interventions concentrated largely on preventing exposure and reducing behaviours associated with transmission. Abstinence, faithfulness to an uninfected partner, consistent condom use, safe blood transfusion practices, avoidance of contaminated needles and public education became central components of prevention campaigns.
Condoms gradually emerged as one of the most recognisable tools in the global HIV prevention response. Their importance was rooted in their relatively low cost, accessibility and ability to provide a physical barrier against HIV transmission during sexual intercourse when correctly and consistently used.
Yet, despite their effectiveness, condom promotion encountered significant social and behavioural obstacles. In some relationships, women lacked the bargaining power to negotiate condom use. Economic dependence, gender inequality, fear of violence, cultural expectations and misinformation frequently undermined consistent utilisation.
Thus, although condoms represented an important scientific and public health achievement, their effectiveness in real-life situations depended substantially on human behaviour and the willingness of sexual partners to use them correctly and consistently.
The subsequent decades witnessed the institutionalisation of HIV prevention programmes, with greater emphasis on voluntary counselling and testing, prevention of mother-to-child transmission, blood safety, targeted interventions and community-based awareness campaigns. The establishment of UNAIDS in 1996 further strengthened international coordination of HIV prevention, treatment and advocacy.
Meanwhile, the introduction of highly active antiretroviral therapy transformed HIV management and laid the foundation for an entirely new understanding of prevention.
One of the most significant developments in the history of the HIV response was the scientific recognition that effective treatment could also prevent transmission. Research established that antiretroviral therapy could suppress HIV replication and reduce viral load to undetectable levels.
This understanding eventually produced the widely recognised public health principle, Undetectable = Untransmittable (U=U).
The principle establishes that people living with HIV who achieve and maintain an undetectable viral load through effective treatment do not sexually transmit the virus.
This scientific development challenged longstanding misconceptions and demonstrated that HIV prevention could no longer be separated from testing, treatment, adherence and sustained viral suppression. It also strengthened the argument for expanding access to HIV testing and ensuring that people diagnosed with the virus receive timely and effective treatment.
Another important development was the expansion of programmes aimed at preventing mother-to-child transmission, demonstrating that HIV transmission during pregnancy, childbirth and breastfeeding could be substantially reduced through appropriate clinical interventions.
Yet, while treatment as prevention transformed the global response, researchers continued exploring ways through which HIV-negative individuals could protect themselves before potential exposure. That search produced one of the most important innovations in modern HIV prevention: oral pre-exposure prophylaxis (PrEP).
The introduction of oral PrEP represented a fundamental departure from traditional HIV prevention approaches. Unlike condoms, which provide a physical barrier against exposure, PrEP involves HIV-negative individuals taking prescribed antiretroviral medication before potential exposure to HIV. The objective is to ensure that sufficient medication is present in the body to prevent the virus from establishing a lasting infection.
In 2012, the United States Food and Drug Administration (FDA) approved Truvada for HIV prevention. Three years later, in September 2015, WHO recommended daily oral PrEP containing tenofovir disoproxil fumarate as an additional prevention option for people at substantial risk of HIV infection. The development was particularly important because it expanded individuals' ability to protect themselves without depending exclusively on their partners' willingness to use condoms. For women experiencing unequal relationships, individuals with partners whose HIV status or viral suppression was uncertain, sex workers and other populations experiencing substantial exposure risks, oral PrEP introduced an additional layer of protection.
Nevertheless, its effectiveness depends on correct use and adherence to the prescribed regimen. Daily medication can become difficult to maintain because of forgetfulness, stigma, travel, medication stock-outs, economic difficulties and interruptions in healthcare access. Some users also experience anxiety about carrying medication that others might mistakenly interpret as HIV treatment. These challenges created the need for longer-acting alternatives that could reduce the frequency of medication administration without compromising preventive effectiveness.
The development of long-acting injectable cabotegravir introduced another significant milestone.
Cabotegravir belongs to a class of antiretroviral medicines known as integrase strand transfer inhibitors. It works by interfering with the HIV enzyme responsible for integrating the virus's genetic material into human cells.
Its prevention potential was established through major clinical studies, particularly HIV Prevention Trials Network (HPTN) 083 and HPTN 084.The United States FDA approved injectable cabotegravir, marketed under the brand name Apretude, for HIV prevention in December 2021.
WHO subsequently recommended CAB-LA as an additional HIV prevention option in 2022. Unlike daily oral PrEP, cabotegravir is administered through injections, with maintenance doses generally given every two months following the initiation schedule. The innovation was particularly significant for individuals who experienced difficulties maintaining daily medication routines or preferred a more discreet prevention option.
However, CAB-LA also introduced new service-delivery requirements. Users must maintain scheduled appointments, undergo appropriate HIV testing and receive clinical monitoring. Missed injections and discontinuation require careful management because cabotegravir can remain in the body at gradually declining concentrations after the last dose.
This pharmacological tail creates a potential risk of drug resistance if HIV infection occurs while drug concentrations are inadequate. Consequently, healthcare professionals must provide appropriate counselling and alternative prevention arrangements when injections are discontinued.The development demonstrated that reducing the frequency of medication administration could expand prevention choices, but it could not eliminate the need for consistent healthcare engagement.
Perhaps the most remarkable recent development in HIV prevention is lenacapavir. Unlike cabotegravir, which targets the integrase enzyme, lenacapavir targets the HIV capsid protein, a structural component that plays several essential roles in the virus's replication cycle.
By interfering with the capsid, the medicine disrupts multiple stages of HIV replication. Originally developed as a treatment for people living with multidrug-resistant HIV, lenacapavir subsequently attracted international attention following remarkable clinical trial results demonstrating its potential as a preventive intervention.
Two major clinical studies, PURPOSE 1 and PURPOSE 2, were particularly influential.
PURPOSE 1 investigated HIV prevention among adolescent girls and young women in South Africa and Uganda. Its findings, published in 2024, recorded zero HIV infections among participants who received lenacapavir in the primary efficacy analysis.
PURPOSE 2 examined prevention among cisgender men and gender-diverse people who have sex with men and also demonstrated substantial preventive effectiveness. The findings generated considerable international interest. On June 18, 2025, the United States FDA approved injectable lenacapavir under the brand name Yeztugo for HIV PrEP. In July 2025, WHO recommended twice-yearly injectable lenacapavir as an additional HIV prevention option within comprehensive combination prevention programmes.
The significance is straightforward. Whereas daily oral PrEP requires consistent medication-taking and CAB-LA requires maintenance injections approximately every two months, lenacapavir offers a maintenance injection schedule of approximately six months.
For individuals experiencing difficulties with daily adherence, privacy concerns, stigma or frequent clinic attendance, this represents an important advancement.
Nevertheless, six-monthly administration must not be misunderstood as six months without healthcare responsibilities.
Individuals must undergo appropriate HIV testing, clinical assessment, initiation procedures and subsequent follow-up in accordance with applicable guidelines.
Lenacapavir is neither an HIV vaccine nor a cure. It is a preventive medication intended for eligible individuals who have tested HIV-negative. Its emergence is therefore an important scientific milestone, not a declaration that the HIV epidemic has been defeated.
For Nigeria, the evolution of HIV prevention carries particular significance. The country has historically relied on condom promotion, behavioural interventions, HIV testing, prevention of mother-to-child transmission, blood safety and community mobilisation. The introduction of oral PrEP expanded the national prevention toolkit. According to UNAIDS documentation, Nigeria expanded oral PrEP service delivery from 15 pilot facilities in 2018 to more than 400 facilities across 31 states by 2024.
However, the same UNAIDS reporting highlights an important concern: approximately 43,000 people were receiving oral PrEP in November 2024, but reported numbers fell below 6,000 by April 2025 amid significant funding disruptions.
This development underscores a difficult reality: expanding the availability of prevention interventions requires more than scientific innovation. It requires dependable financing, commodity procurement, effective distribution and sustained community-level implementation.
Nigeria subsequently moved towards introducing long-acting injectable prevention technologies. On March 31, 2026, WHO announced Nigeria's introduction of lenacapavir for HIV prevention, describing the country as one of nine early adopters globally. The initial rollout covers eight states: Ebonyi, Anambra, Benue, Akwa Ibom, Cross River, Gombe, Kwara and the Federal Capital Territory.
The programme is supported by the Federal Ministry of Health and Social Welfare, WHO, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and other development partners. More than 70 health facilities across 10 states had been assessed for readiness, including requirements relating to healthcare worker training, supply management, counselling and monitoring.
Nigeria is also expected to receive approximately 180,000 doses by 2028 under the implementation arrangements announced by WHO. These developments place the country within the emerging international movement towards long-acting HIV prevention. However, the real test will be whether the intervention can reach the people for whom it is intended, particularly vulnerable populations and communities with limited access to specialised healthcare services.
For Ebonyi State, the introduction of lenacapavir presents an important opportunity to strengthen its HIV prevention response. It would be recalled that Nigerian Pilot had earlier reported that the Federal Government, in collaboration with the Global Fund and other development partners, commenced the rollout of injectable HIV prevention across eight states, with Ebonyi among the beneficiaries.
The Executive Secretary of the Ebonyi State Agency for the Control of AIDS (EBOSACA), Prince Chibueze Andrew Iteshi, confirmed the development to journalists in Abakaliki. He explained that the medication would be administered twice yearly and that designated health facilities had been identified for the programme.
According to him, beneficiaries would undergo appropriate medical assessments, including HIV screening and other clinical investigations, before initiation. Among the facilities identified for the intervention were Alex Ekwueme Federal University Teaching Hospital, Ebonyi State University General Hospital, Uburu, General Hospital, Ezzamgbo, General Hospital, Onueke, St Patrick Mile 4 Hospital, Police Clinic, Abakaliki, ROMEC Maternity Hospital and the Ebonyi One Stop Shop.
Iteshi described the intervention as an important addition to the state's HIV prevention services. He stated: "It's true. The injection is taken every six months and Ebonyi is among the eight states where the programme is currently being implemented. It is accessible within town through designated health facilities."
However, the announcement raises questions that deserve continuous independent journalistic investigation.
How many people have actually received the injections since the programme commenced? What is the number of available doses in Ebonyi? Are the identified facilities fully operational for the intervention? How many healthcare professionals have received specialised training? Are rural communities adequately informed about eligibility, availability and access? What mechanisms exist to ensure that beneficiaries do not miss subsequent appointments? These are not merely administrative questions. They are essential indicators of whether a scientific breakthrough is producing measurable public health benefits.
Being selected as a beneficiary state is an important starting point, but implementation, continuity and equitable access will ultimately determine the programme's impact. It was against this background that NACA and IHVN convened journalists for the two-day national media training on HIV PrEP in Lagos.
The Director-General of NACA, Dr Temitope Ilori, represented by the Head of Public Relations and Protocol, Toyin Aderibigbe, described the media as an indispensable partner in Nigeria's HIV prevention response. She observed that although the country had sustained gains in HIV testing, treatment and care, prevention remained a critical component of the national response.
According to her, the availability of prevention services alone was insufficient without accurate information enabling Nigerians to understand their options, identify service locations and feel confident accessing appropriate interventions. Her position addressed one of the most persistent problems confronting HIV prevention: the gap between scientific knowledge and public understanding.
She cautioned that inaccurate or sensational reporting could create fear, reinforce stigma and discourage individuals from seeking prevention services. She therefore urged journalists to report HIV prevention "accurately, responsibly, respectfully and without stigma".
The NACA Director-General challenged participants to go beyond reporting technical information and develop compelling stories capable of answering questions ordinary Nigerians might otherwise be reluctant to ask. These include who qualifies for PrEP, how it works, available prevention options, possible limitations and where services can be accessed. She further emphasised the growing influence of digital platforms, particularly among young people, stressing that credible health information must be available wherever audiences seek information.
Importantly, she called for sustained engagement between NACA, media organisations, development partners and the wider digital communication community rather than treating the training as an isolated intervention.
She linked the engagement to Nigeria's National Strategic Plan for HIV and AIDS 2026–2030, which emphasises sustainability, innovation, stronger partnerships and community engagement.
The intervention by IHVN also highlighted the importance of effective demand creation. The Chief Executive Officer of IHVN, Dr Patrick Dakum, represented by the Senior Programme Manager, Prevention, Comfort Amina Ochigbo, commended NACA for bringing journalists into the prevention conversation.
Ochigbo disclosed that IHVN was working with NACA and other partners to support the successful implementation of the PrEP pilot programme across eight states. She emphasised that communities must receive correct information devoid of misconceptions if the programme is to achieve its intended objectives. She also highlighted the importance of media engagement in supporting demand generation, public understanding and the eventual scale-up of HIV prevention services.
Similarly, the National AIDS, Viral Hepatitis and Sexually Transmitted Infections (STIs) Control Programme (NASCP), through its focal person for Advocacy, Communications and Social Mobilisation, Mrs Uchechi Nzenwata, stressed the importance of collaboration between health institutions and the media.
She maintained that responsible reporting was essential to building public trust and ensuring that individuals made informed decisions about HIV prevention.
One of the defining features of the training was its emphasis on moving journalists beyond superficial knowledge of HIV and AIDS.
One of the facilitators, the Principal Partner of Kent Consult Limited, Abuja, Dr Segun Oyedeji, took participants through the fundamentals of HIV, AIDS, transmission, prevention and the importance of accurate public communication.
His presentations emphasised that journalists must understand the subject sufficiently to distinguish scientific facts from popular misconceptions. Through interactive discussions and practical exercises, participants examined common myths surrounding HIV transmission.
These included misconceptions that HIV could be transmitted through handshakes, hugging, sharing food and drinks, mosquito bites and ordinary social contact. The presentations reinforced the scientific position that HIV is not transmitted through these everyday interactions. This distinction remains important because misinformation continues to fuel discrimination against people living with HIV.
The training also addressed the relationship between HIV infection and AIDS, explaining that HIV attacks the immune system, particularly CD4 cells, while AIDS represents the advanced stage of HIV infection when severe immune damage and certain opportunistic illnesses may occur.
Another important area of discussion was the prevention of mother-to-child transmission.
Participants were exposed to how appropriate antiretroviral treatment, clinical monitoring and established prevention protocols can significantly reduce the possibility of transmission during pregnancy, childbirth and breastfeeding. The central lesson was that an HIV diagnosis must not be confused with an automatic death sentence or an inability to have healthy children.
People living with HIV can live long and productive lives with effective treatment.
While much of the international attention surrounding HIV prevention is currently directed towards injectable technologies, the Lagos training also provided an important reminder that conventional prevention methods remain relevant. The Senior Prevention Programme Manager of the AIDS Healthcare Foundation Nigeria (AHF-Nigeria), Adeleye Taofeek, delivered an extensive presentation on condom use, correct application, storage, lubricants and the importance of combination prevention.
His presentation challenged some of the misconceptions responsible for inconsistent condom use.
He explained that condom sizes, quality, storage conditions and correct application could influence users' experiences and the effectiveness of the intervention. He cautioned against exposing condoms to excessive heat, noting that improper storage could compromise their integrity. He also demonstrated the importance of checking expiry dates, avoiding sharp objects and teeth when opening condom wrappers, and using appropriate lubricants to reduce friction and the possibility of breakage.
The presentation further introduced participants to the female condom as another prevention option. The broader message was that condom promotion must be supported by practical education rather than simply distributing commodities. More importantly, the emergence of PrEP must not be interpreted as a reason to abandon condoms.
Oral PrEP, CAB-LA and lenacapavir are specifically designed to prevent HIV infection. They do not provide comprehensive protection against other sexually transmitted infections, such as gonorrhoea, syphilis, chlamydia and genital herpes.
Condoms also remain an important means of reducing the risk of unintended pregnancy when used correctly.
Consequently, the appropriate public health approach is combination prevention, allowing individuals to make informed choices based on their circumstances and healthcare needs.
Despite the extraordinary progress recorded in HIV prevention, several challenges remain unresolved. The first is affordability. Innovative medicines cannot deliver population-level impact if their procurement, distribution and administration remain beyond the reach of those who need them. Nigeria must therefore develop sustainable financing arrangements that reduce excessive dependence on external development partners.
The second is stigma. Some individuals avoid prevention services because they fear being mistaken for people living with HIV or being judged because of their sexual behaviour. This is particularly concerning among young people and vulnerable populations who may already face barriers to healthcare access. The third is healthcare infrastructure.
Long-acting PrEP requires trained personnel, dependable supplies, accessible testing facilities, clinical monitoring and effective patient follow-up systems. A six-monthly injection may reduce the frequency of medication administration, but it does not eliminate the need for a functional healthcare system.
The fourth is geographical inequality.
There is a danger that people in major cities will benefit from new prevention technologies while rural populations remain inadequately informed or excluded.
For Ebonyi, this means that implementation should extend beyond designated urban facilities to include effective community engagement, appropriate referral arrangements and reliable information for people in rural communities.
The fifth is continuity. What happens when a beneficiary misses an appointment, relocates or discontinues the medication? How will health workers ensure appropriate HIV testing and alternative prevention arrangements?
These questions require clear clinical protocols and dependable follow-up mechanisms.
Perhaps the most important lesson from the NACA-IHVN engagement is that the media must evolve alongside medical science. Journalists cannot effectively communicate HIV prevention when their understanding remains limited to conventional condom promotion or general awareness campaigns. The emergence of oral PrEP, CAB-LA and lenacapavir requires a more sophisticated level of health reporting.
It demands journalists who can interpret clinical evidence, distinguish treatment from prevention, understand medication schedules, interrogate public health data and explain scientific developments without exaggeration.
Equally important is the responsibility to hold institutions accountable.
When government announces the introduction of a new prevention technology, journalists should investigate the number of available doses, distribution arrangements, operational facilities, beneficiaries reached and funding commitments.
When health agencies report increased awareness, journalists should examine whether that awareness translates into actual service utilisation. When development partners announce financial support, journalists should investigate sustainability and the extent to which domestic institutions are preparing to assume greater responsibility. This is the difference between conventional health reporting and development journalism that contributes to measurable public health improvements.
Participants at the Lagos training acknowledged the importance of the engagement and pledged to deploy the knowledge acquired through their respective platforms. Their reflections also highlighted the need for continued capacity-building, improved media financing and more direct community engagement to ensure that information reaches those who need it. The historical progression from condoms to daily oral PrEP, long-acting cabotegravir and twice-yearly lenacapavir demonstrates the remarkable capacity of science to transform public health.
Four decades ago, HIV prevention was largely characterised by fear, limited medical knowledge and dependence on behavioural interventions. Today, individuals have access to several scientifically established prevention options, including medicines that can substantially reduce their risk of acquiring HIV. Yet scientific advancement must not be confused with the achievement of universal protection.
Nigeria's participation in the early introduction of lenacapavir is an important development, but the country's success will depend on how effectively it addresses affordability, supply continuity, public awareness, healthcare infrastructure and equitable distribution.
For Ebonyi State, the responsibility is particularly clear. The inclusion of the state among the eight initial beneficiaries must translate into measurable improvements in access, public understanding and prevention outcomes.
EBOSACA, healthcare institutions, civil society organisations, development partners and media organisations must sustain collaboration to ensure that the intervention reaches eligible individuals without discrimination. NACA and IHVN must also ensure that the media engagement initiated in Lagos becomes a sustained partnership supported by accessible technical information, regular updates and opportunities for independent reporting.
Ultimately, the future of HIV prevention should not be defined by a competition between condoms, tablets and injections. Each intervention has its place within a comprehensive prevention framework.
The objective should be to expand choices, remove barriers and ensure that individuals can access scientifically appropriate protection without being constrained by poverty, stigma, ignorance or geographical disadvantage.
The journey from condoms to six-monthly injections is undoubtedly a remarkable story of scientific progress.
But the real breakthrough will come when these innovations move beyond research findings, international recommendations and government announcements to become accessible, affordable and sustainable services in ordinary communities.
That is when the promise of modern HIV prevention will begin to translate into a genuinely healthier future. And that is when Nigeria's ambition of ending AIDS as a public health threat will move closer to reality.

